Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind multicenter trial of inhaled ambroxol hydrochloride solution for expectoration in lower respiratory tract infection
CTR20200267Phase 3Active
- Sponsor
- Wanbangde Pharmaceutical Holding Group
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ambroxol in pulmonary infection, chronic bronchitis (CB), pneumonia, chronic obstructive pulmonary disease (COPD), sponsored by Wanbangde Pharmaceutical Holding Group. Started Mar 2020; status: active.
02
Drugs
ambroxol
03
Conditions
pulmonary infectionchronic bronchitis (CB)pneumoniachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20200267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200267.